These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 24827891)

  • 1. Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.
    Zhanel GG; Denisuik A; Vashisht S; Yachison C; Adam HJ; Hoban DJ
    J Antimicrob Chemother; 2014 Sep; 69(9):2448-52. PubMed ID: 24827891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum beta-lactamase-producing Escherichia coli using an in vitro model.
    Zhanel GG; Baudry P; Vashisht V; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2008 Mar; 61(3):643-6. PubMed ID: 18238885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
    Zhanel GG; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.
    Tängdén T; Adler M; Cars O; Sandegren L; Löwdin E
    J Antimicrob Chemother; 2013 Jun; 68(6):1319-26. PubMed ID: 23478794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).
    Hawser SP; Bouchillon SK; Lascols C; Hackel M; Hoban DJ; Badal RE; Cantón R
    Clin Microbiol Infect; 2012 Mar; 18(3):253-9. PubMed ID: 21635662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs.
    Hagihara M; Crandon JL; Urban C; Nicolau DP
    J Antimicrob Chemother; 2013 Jul; 68(7):1616-8. PubMed ID: 23475648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure.
    Ungphakorn W; Tängdén T; Sandegren L; Nielsen EI
    J Antimicrob Chemother; 2016 Sep; 71(9):2521-33. PubMed ID: 27330073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.
    Kiffer CR; Kuti JL; Eagye KJ; Mendes C; Nicolau DP
    Int J Antimicrob Agents; 2006 Oct; 28(4):340-4. PubMed ID: 16930951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model.
    Maglio D; Banevicius MA; Sutherland C; Babalola C; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2005 Jan; 49(1):276-80. PubMed ID: 15616306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.
    Tamayo J; Orden B; Cacho J; Cuadros J; Gomez-Garces JL; Alos JI
    Rev Esp Quimioter; 2007 Sep; 20(3):334-8. PubMed ID: 18080031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Underlying mechanisms of carbapenem resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases.
    Baroud M; Dandache I; Araj GF; Wakim R; Kanj S; Kanafani Z; Khairallah M; Sabra A; Shehab M; Dbaibo G; Matar GM
    Int J Antimicrob Agents; 2013 Jan; 41(1):75-9. PubMed ID: 23142087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro emergence of ertapenem resistance in Escherichia coli producing extended-spectrum β-lactamase].
    Villar HE; Jugo MB; Visser M; Hidalgo M; Hidalgo G; Maccallini GC
    Rev Esp Quimioter; 2014 Mar; 27(1):51-5. PubMed ID: 24676243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
    Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
    Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model.
    Zhanel GG; Parkinson K; Higgins S; Denisuik A; Adam H; Pitout J; Noreddin A; Karlowsky JA
    Diagn Microbiol Infect Dis; 2017 Jul; 88(3):271-275. PubMed ID: 28483306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model.
    Zhanel GG; Yachison C; Nichol K; Adam H; Noreddin AM; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2012 Jul; 67(7):1706-11. PubMed ID: 22467630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.